{"id":44321,"date":"2022-05-25T12:01:13","date_gmt":"2022-05-25T10:01:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biopharmaceuticals-contract-manufacturing-market-analysis-research-report-2022-2030-merger-acquisitions-in-cmo-industry-trading-of-cmos-at-strong-ev-ebitda-multiples-current-trends-researchandm\/"},"modified":"2022-05-25T12:01:13","modified_gmt":"2022-05-25T10:01:13","slug":"biopharmaceuticals-contract-manufacturing-market-analysis-research-report-2022-2030-merger-acquisitions-in-cmo-industry-trading-of-cmos-at-strong-ev-ebitda-multiples-current-trends-researchandm","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biopharmaceuticals-contract-manufacturing-market-analysis-research-report-2022-2030-merger-acquisitions-in-cmo-industry-trading-of-cmos-at-strong-ev-ebitda-multiples-current-trends-researchandm\/","title":{"rendered":"Biopharmaceuticals Contract Manufacturing Market Analysis\/Research Report 2022-2030: Merger & Acquisitions in CMO industry, Trading of CMOs at Strong EV\/EBITDA Multiples, Current Trends – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, by Service (Upstream, Downstream, Fill\/Finish), by Product (Biologics), by Region and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global biopharmaceuticals contract manufacturing market size is expected to reach USD 27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030.\n<\/p>\n

\nGrowing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs).\n<\/p>\n

\nContract manufacturers are engaged in broadening their service portfolio to meet the companies’ demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.\n<\/p>\n

\nThe reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio.\n<\/p>\n

\nThe supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics.\n<\/p>\n

\nThus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.\n<\/p>\n

\nThe future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market.\n<\/p>\n

\nFor instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.\n<\/p>\n

\nBiopharmaceuticals Contract Manufacturing Market Report Highlights<\/strong>\n<\/p>\n